Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
August 29 2022 - 8:04AM
Business Wire
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology
company, today announced the continuing success of PolyTope®
TATX-03 antibody combination therapy to neutralize variants of
concern of the COVID-19 causative virus, including the latest
Omicron BA.5 subvariant, validated by an independent research
organization in an authentic virus assay.
Research was conducted by the Max von Pettenkofer Institute,
part of the Medical Faculty of the Ludwig-Maximilians-University
(LMU, Munich, Germany), who is world-renowned for their research
and diagnostic services on SARS-CoV-2. The blinded studies examined
the efficacy of IPA’s PolyTope® TATX-03 antibody combination
therapy alongside in-house derived formulations of several
commercially approved antibodies. Authentic isolates of virus
variants tested in vitro by the LMU institute included 20E (EU1;
B.1.177), Alpha (B1.1.7), Beta (B.1.351), Delta (B.1.617.2),
Omicron lineages BA.1 (B.1.1.529.1), BA.1.1 (B.1.1.529.1.1), BA.2
(B.1.1.529.2), and BA.5 (B.1.1.529.5). Whereas commercially
licensed products had difficulty to protect the susceptible cells
against some of the listed coronavirus (sub)variants, IPA’s
PolyTope® TATX-03 was able to neutralize all (sub)variants tested,
including the currently dominant Omicron BA.5 subvariant, which has
been described to display increased immune evasion compared to
BA.1, BA.2 and pre-Omicron variants. As the spike trimer of the
BA.4 Omicron variant is identical to BA.5 glycoprotein, the Company
anticipates that the consistent neutralizing potency of TATX-03
hold true for this variant.
IPA’s Chief Scientific Officer (CSO), Dr. Ilse Roodink, stated:
“While underway to the first clinical trials of our PolyTope® in
humans, this independent confirmation of the strength of our
rationally designed combination therapy using authentic virus
variants is very valuable for our ongoing discussion with the
authorities. With the rapid evolution of Omicron and its variants,
the need for a sustainable therapy to SARS-CoV-2 infection becomes
increasingly evident”. She continued, “While our first-generation
TATX-03 therapy has proven its resilience in vitro, we are
confident about the anticipated in vivo efficacy in humans, as some
components of our cocktail are able to mediate anti-viral effects
through mechanisms which may enhance the already proven performance
in the prior in vitro neutralization assays.”.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and
technology company that leverages network biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release include, but are not limited to, statements regarding the
Company’s ability to successfully submit a clinical use application
with respect to PolyTope® TATX-03, statements regarding regulatory
approvals, statements regarding the potential of IPA’s PolyTope®
TATX-03 to provide strong anti-viral effects against
SARS-CoV-2/COVID-19 disease or any variant of the virus as either a
prophylactic (preventative) or treatment (therapeutic), or to
retain efficacy over time, and statements regarding the
commencement date of first-in-human clinical phase trial. In
respect of the forward-looking information contained herein, the
Company has provided such statements and information in reliance on
certain assumptions that management believed to be reasonable at
the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the Company may not be successful in timely submission
of an application for regulatory approval, developing its PolyTope®
TATX-03 through the successful and timely completion of clinical
trials, or may not receive all regulatory approvals to commence and
then continue clinical trials of PolyTope® TATX-03, as well as
those risks discussed in the Company’s Annual Information Form
dated July 29, 2022 (which may be viewed on the Company’s profile
at www.sedar.com) and the Company’s Form 40-F, dated July 29, 2022
(which may be viewed on the Company’s profile at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. Accordingly, readers
should not place undue reliance on forward-looking information
contained in this news release.
The forward-looking statements contained in this news release
are made as of the date of this release and, accordingly, are
subject to change after such date. The Company does not assume any
obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220829005367/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jul 2023 to Jul 2024